NET SALES AS OF JUNE 30, 2019
Longjumeau, July 24, 2019
PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its net sales as of June 30, 2019.
The PCAS Group has generated consolidated net sales of €102.3 million as of June 30, 2019, representing an increase of 1.9% compared to the same period during the previous financial year (+0.6% at constant exchange rate).
| In millions of euros | 2019 | 2018 | % change | 2019 At a constant exchange rate | % change | |||||
| Net sales as of 30 June | 102.3 | 100.4 | 1.9% | 101.0 | 0.6% | |||||
| Pharmaceutical Synthesis | 62.5 | 61.6 | 1.3% | 61.5 | -0.3% | |||||
| Fine Specialty Chemicals | 39.8 | 38.7 | 2.9% | 39.5 | 2.0% |
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business generated net sales of €62.5 million, +1.3% compared to 2018 (-0.3% at constant exchange rate). The operational difficulties mentioned during the first quarter are continuing, even though indicators are showing some improvement. Problems in sourcing certain raw materials, the cancelation of a major order and a lower level of demand for some of our proprietary products played a role in slowing down our net sales growth.
Fine Specialty Chemicals
Net sales of Fine Specialty Chemicals totaled €39.8 million, +2.9% compared to 2018 (+2.0% at constant exchange rate), with a very strong growth in Fine Chemicals and Electronics due to robust demand from our customers and several new projects, partly offset by a significant slowdown in Lubricants and a fall in the development of enzymes for bio-catalysis (Protéus).
Outlook for the current year
In 2019, the Group's net sales should show a slight growth despite the operational difficulties that continued throughout the first six months of the year in the Pharmaceutical Synthesis activity and which are currently making it hard to anticipate trends in the Group's results. The costs incurred by the Longjumeau site reorganization announced in November 2018 will also have a significant negative impact on the Group's results for the first six months of 2019.
NEXT FINANCIAL DISCLOSURE:
First half 2019 earnings report, September 5, 2019
ABOUT PCAS
PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 9% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €206.7 million in 2018 and employs close to 1 100 people in six countries.
To find out more about PCAS: www.pcas.com
| PCAS | Newcap |
| Frédéric Desdouits / Eric Moissenot PCAS | Emmanuel Huynh / Louis-Victor Delouvrier NewCap Communication financière et Relations Investisseurs |
| Tel.: +33 1 69 79 61 32 www.pcas.com | Tel.: +33 1 44 71 98 53 pcas@newcap.eu |
Attachment